Drugs / GNR-055
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04539340 | Feb → Sep 2020 | mucopolysaccharidosis type 2 | AO GENERIUM | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05208281 | Nov 2021 → Jun 2026 overdue | mucopolysaccharidosis type 2 | AO GENERIUM | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05208281 ↗ |
| Modality | Protein / enzyme biologic | “GNR 055 is a modified enzyme iduronate-2-sulfatase capable of penetrating the blood-brain barrier” NCT04539340 ↗ |
| Route | Intravenous | “Single intravenous administration” NCT04539340 ↗ |